Literature DB >> 3133398

Tissue type plasminogen activator antigen and activity in sickle cell disease.

R B Francis1.   

Abstract

To investigate the hypothesis that diminished endothelial fibrinolysis is present in sickle cell (SS) disease plasma, tissue type plasminogen activator (t-PA) antigen titres were measured before and after a standard stimulus of endothelial t-PA release (venous occlusion of the arm), and plasma t-PA activities after venous occlusion in 33 subjects with SS disease and in 32 healthy subjects. Mean plasma t-PA antigen titres before and after venous occlusion, and mean plasma t-PA activities after venous occlusion did not differ significantly between SS patients and normal subjects. No significant differences in mean t-PA antigen and activity were observed between samples taken from inpatients being treated for acute pain crisis (18 subjects, 30 samples) and samples taken from subjects in the steady state (23 subjects, 26 samples). No consistent differences were seen between painful crisis and steady state samples in eight SS patients studied while in crisis and in the steady state. No correlation was observed between any fibrinolytic variable in SS patients and the overall severity of microvascular occlusive disease as measured by a standard scoring system. It is concluded that the capacity of endothelium to synthesise and release t-PA is not impaired in SS disease, and that excessive inhibition of released t-PA, leading to reduced t-PA activity in plasma is also not a feature of SS disease, either in the steady state or during painful crisis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3133398      PMCID: PMC1141498          DOI: 10.1136/jcp.41.5.490

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  15 in total

1.  Elevated plasma levels of fibrinopeptide A during sickle cell anemia pain crisis--evidence for intravascular coagulation.

Authors:  D A Leichtman; G J Brewer
Journal:  Am J Hematol       Date:  1978       Impact factor: 10.047

2.  Aspirin-dipyridamole prophylaxis of sickle cell disease pain crises.

Authors:  H Chaplin; N Alkjaersig; A P Fletcher; J M Michael; J H Joist
Journal:  Thromb Haemost       Date:  1980-07-15       Impact factor: 5.249

3.  Serial changes in coagulation and viscosity during sickle-cell crisis.

Authors:  S G Richardson; K B Matthews; J Stuart; A M Geddes; R M Wilcox
Journal:  Br J Haematol       Date:  1979-01       Impact factor: 6.998

4.  Tissue plasminogen activator antigen and activity in disseminated intravascular coagulation: clinicopathologic correlations.

Authors:  R B Francis; U Seyfert
Journal:  J Lab Clin Med       Date:  1987-11

5.  Fibrinolytic activity in the clinical crisis of sickle-cell anaemia.

Authors:  A Mahmood; D M Macintosh; A G Shaper
Journal:  Br Med J       Date:  1967-09-09

6.  Hemostatic alterations accompanying sickle cell pain crises.

Authors:  N Alkjaersig; A Fletcher; H Joist; H Chaplin
Journal:  J Lab Clin Med       Date:  1976-09

7.  Abnormalities in membrane phospholipid organization in sickled erythrocytes.

Authors:  B Lubin; D Chiu; J Bastacky; B Roelofsen; L L Van Deenen
Journal:  J Clin Invest       Date:  1981-06       Impact factor: 14.808

8.  Sickled erythrocytes accelerate clotting in vitro: an effect of abnormal membrane lipid asymmetry.

Authors:  D Chiu; B Lubin; B Roelofsen; L L van Deenen
Journal:  Blood       Date:  1981-08       Impact factor: 22.113

9.  Coagulation fibrinolysis in sickle-cell disease.

Authors:  P A Gordon; G R Breeze; J R Mann; J Stuart
Journal:  J Clin Pathol       Date:  1974-06       Impact factor: 3.411

10.  Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity.

Authors:  R P Hebbel; M A Boogaerts; J W Eaton; M H Steinberg
Journal:  N Engl J Med       Date:  1980-05-01       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.